Accent Therapeutics

Accent Therapeutics describes itself as taking a novel view of cancer, leveraging expertise in genomic instability and small molecule drug discovery. The company states that it looks beyond mutation-specific vulnerabilities to identify and exploit critical cellular dependencies resulting from genomic and chromosomal instability observed in multiple types of cancer, and develops small molecule therapeutics designed to inhibit those targets. It reports having identified numerous high-value programs with potential to benefit large patient populations with significant unmet medical need, and describes its team as a highly experienced and collaborative group of 'ACCENTuators' focused on translating science into therapies for patients.

Accent Therapeutics presents itself as a company translating extraordinary science into life-changing therapeutics for patients living with cancer. It states that it takes a novel view of cancer, leveraging industry-leading expertise in genomic instability and small molecule drug discovery, and that it looks beyond mutation-specific vulnerabilities to identify and exploit critical cellular dependencies resulting from genomic and chromosomal instability observed in multiple types of cancer. The company reports that its approach has identified numerous high-value programs with the potential to benefit large patient populations with significant unmet medical need. Its latest news items reference a Phase 1/2 study of ATX-295 and data on ATX-295, described as a novel KIF18A inhibitor, presented at 2026 scientific meetings.

Leveraging industry-leading expertise in genomic instability and small molecule drug discovery to develop therapeutics for patients living with cancer.

• ATX-295

  Described as a novel KIF18A inhibitor; subject of a Phase 1/2 study.

1. 1Accent Therapeutics | Translating extraordinary science into life-changing therapeutics for patients living with canceraccenttx.com
2. 2Accent Therapeutics (United States)wikidata.org